Creative Medical Technology (US:CELZ)2026-03-20 20:45Clinical Trials and FDA Approvals - The FDA cleared the Company's Type I Diabetes (CELZ-201 CREATE-1) IND application, allowing the initiation of a Phase I/II clinical trial with patient recruitment starting in September 2023[23]. - The Company received FDA clearance for a Phase I/II trial of AlloStemSpine® Chronic Lower Back Pain (CELZ-201 ADAPT) in September 2023, enrolling 30 individuals[28]. - In March 2024, the Company secured FDA authorization for expanded access therapy using CELZ-201 to manage abnormal glucose tolerance in high-risk individuals[31]. - The FDA granted Fast Track designation to CELZ-201-DDT in August 2025, expediting its path to market and patient access[40]. - The AlloStem™ Clinical Cell Line (CELZ-200) was developed to support multiple programs, including treatments for Type I Diabetes and chronic lower back pain[22]. - The FDA clearance for the AlloStemSpine® Chronic Lower Back Pain trial will enroll 30 individuals to evaluate safety and efficacy[28]. - The AlloStem™ program is in clinical phase, utilizing perinatal tissue-derived cells for regenerative therapies, with FDA Drug Master Files registered for interventional drug products[50]. - The ImmCelz™ (CELZ-100) technology is in pre-clinical trials, focusing on reprogramming a patient's immune cells for various treatments[51]. - The AlloStem™ (CELZ-201-DDT) program demonstrated an excellent safety profile with no serious adverse events reported in the first cohort of the clinical trial[38]. - The company completed patient enrollment in the ADAPT clinical trial for CELZ-201 in December 2025, transitioning to the next phase focused on follow-up and data analysis[43]. Efficacy and Outcomes - In April 2023, a study reported a 93% efficacy rate in patients treated with CELZ-001 for Type 2 Diabetes, demonstrating at least a 50% reduction in insulin requirement[27]. - The StemSpine® procedure demonstrated an efficacy rate of 87% in a three-year follow-up study, with no serious adverse effects reported[69]. - The mean pain score for patients in the pilot study decreased from 8.9 at baseline to 1.3 at 12 months, indicating significant improvement in mobility and pain reduction[67]. - The OvaStem™ procedure showed significant efficacy for treating medical refractory Primary Ovarian Insufficiency (POI), resulting in the successful birth of healthy babies without serious adverse effects[75]. - In February 2023, positive one-year follow-up data for the StemSpine® pilot study demonstrated continued efficacy for treating chronic lower back pain[24]. Financial Activities and Investments - On October 23, 2024, the company sold 418,552 shares at $4.42 per share, raising approximately $1.6 million in net proceeds from a registered direct offering and concurrent private placement[44]. - On March 6, 2025, the company entered into agreements for the exercise of existing warrants, generating gross proceeds of $3.7 million from the exercise of 837,104 shares at $4.42 per share[45]. - On October 29, 2025, the company raised approximately $4.2 million from the exercise of warrants for 1,116,136 shares at $3.75 per share, with new warrants for up to 2,790,340 shares at $2.86 per share[46]. - The company contributed $43,200 to Bionance for an investment in Applife Digital Solutions, indicating strategic financial partnerships[42]. Intellectual Property and Licensing - The company has a robust intellectual property portfolio with seven issued patents and thirty-nine pending applications related to stem cell utilization in various medical fields[78]. - The company acquired U.S. Patent No. 9,598,673 for the treatment of lower back pain, with an initial payment of $100,000, including cash and stock[84]. - The company has ongoing obligations under the Patent Purchase Agreement, including $100,000 upon filing an IND with the FDA and $200,000 upon dosing the first patient in a Phase 1-2 clinical trial[88]. - The company has entered into a Patent License Agreement with Jadi Cell, LLC, granting access to proprietary processes for expanding the master cell bank, with an initial license fee of $250,000 paid in stock[86][87]. - The company is required to pay a 5% royalty on gross sales of products derived from its patents for five years following the first sale[88]. - Trademark registrations have been obtained for CaverStem®, StemSpine®, AlloStemSpine®, and FemCelz®, with additional applications pending for several other products[90]. Regulatory Environment - The FDA regulates the company's stem cell treatments under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act, imposing substantial requirements on clinical development and marketing[93][95]. - The FDA's approval process for drugs and biologics typically involves multiple phases of clinical trials, which can be time-consuming and expensive[102]. - The FDA can impose enforcement actions such as fines and product recalls if regulatory compliance is not met, which could adversely affect the company[100]. - The FDA's premarket clearance process can take from three months to four years, depending on the type of application submitted[122]. - If products are classified as medical devices, the company must comply with FDA regulations, which could lead to significant enforcement actions if not adhered to[123]. Strategic Partnerships and Initiatives - The partnership with Greenstone Biosciences aims to leverage AI for developing hypoimmunogenic iPSC-derived pancreatic islet cells, enhancing insulin secretion capabilities[36]. - The company announced a national BioDefense Veterans Initiative to address long-term effects of toxic burn pit exposure, utilizing AI and iPSC technology[41]. - In July 2024, the company initiated a program combining AI with proprietary iPSC technology to diagnose and treat patients exposed to biological and chemical weapons[34]. - The company announced an expanded agreement with Greenstone Biosciences Inc. in February 2025 to leverage AI for developing iPSC technology for diabetes treatment[36]. - In October 2025, the company launched the BioDefense Veterans Initiative to address long-term effects of toxic burn pit exposure, partnering with Greenstone Biosciences for AI and iPSC development[41]. Market Position and Competition - The company is competing with larger pharmaceutical and biotechnology firms in the regenerative medicine sector, which is rapidly evolving[91]. - Competitors in regenerative medicine for disc and spine treatments include Mesoblast, Longeveron, BioRestorative Therapies, and DiscGenics[92]. - The healthcare industry is highly regulated in the U.S., with substantial requirements imposed by the FDA and other regulatory agencies on medical products[93].